Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17110082 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Turner SD, et al. (2007) The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. Cell Signal 19, 740-7 17110082
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

T202-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  B lymphocyte, Jurkat (T lymphocyte), Karpas-299 (T lymphocyte), SU-DHL1 (T lymphocyte)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
anti-IgM increase
increase NPM-ALK translocation product

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  B lymphocyte, Jurkat (T lymphocyte), Karpas-299 (T lymphocyte), SU-DHL1 (T lymphocyte)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
anti-IgM increase
increase NPM-ALK translocation product

T185-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  B lymphocyte, Jurkat (T lymphocyte), Karpas-299 (T lymphocyte), SU-DHL1 (T lymphocyte)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
anti-IgM increase
increase NPM-ALK translocation product

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  lymphoma, anaplastic large cell lymphoma, T cell lymphoma
 Relevant cell lines - cell types - tissues:  B lymphocyte, Jurkat (T lymphocyte), Karpas-299 (T lymphocyte), SU-DHL1 (T lymphocyte)
 Cellular systems studied:  cell lines, primary cells
 Species studied:  human, mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
EGF increase
anti-IgM increase
increase NPM-ALK translocation product

Y156-p - NPM-ALK (human) ▲
Orthologous residues
NPM‑ALK (human): Y156‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  gene is NPM-ALK translocation product
Downstream Regulation
 Effect of modification (process):  transcription, altered

Y567-p - NPM-ALK (human) ▲
Orthologous residues
NPM‑ALK (human): Y567‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  gene is NPM-ALK translocation product
Downstream Regulation
 Effect of modification (process):  transcription, altered

Y664-p - NPM-ALK (human) ▲
Orthologous residues
NPM‑ALK (human): Y664‑p
Characterization
 Methods used to characterize site in vivo:  mutation of modification site
 Relevant cell lines - cell types - tissues:  Jurkat (T lymphocyte)
 Cellular systems studied:  cell lines
 Species studied:  human
 Comments:  gene is NPM-ALK translocation product
Downstream Regulation
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.